HHealthcare Read More Eli Lilly launches program to boost employer coverage of obesity drugsMarch 5, 2026 Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
HHealthcare Read More Why Novo Nordisk’s Ireland expansion is key to fighting off Eli LillyMarch 2, 2026 Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
HHealthcare Read More Eli Lilly’s lead in the obesity race gets wider after win against NovoFebruary 26, 2026 In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…
HHealthcare Read More These 4 charts show the scale of Novo Nordisk’s woesFebruary 25, 2026 Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
HHealthcare Read More What’s next for Novo Nordisk’s obesity drug CagriSemaFebruary 24, 2026 A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
HHealthcare Read More Eli Lilly launches Zepbound obesity drug pen with one month of dosesFebruary 23, 2026 An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…